Few prescription drugs have entered the public consciousness as abruptly as Ozempic and Wegovy have in recent years. Novo Nordisk’s brand-name medications have become as synonymous with weight loss as Viagra and Cialis are with erectile dysfunction. But while 2023 has made it clear that these and similar drugs really…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
Mario Castello/Corbis/VCG
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
New research suggests that Eli Lilly’s tirzepatide can boost existing efforts to lose weight. The company’s latest clinical trial found that people who dropped at least 5% of their weight before taking the drug went on to lose substantially more weight than those who took a placebo. Those in the treatment group…
The arms race over the next generation of obesity drugs is continuing to heat up.
The makers of two popular but off-label weight loss drugs are now being sued over complications allegedly linked to their use. This week, a Louisiana woman filed a complaint against the companies Novo Nordisk and Eli Lilly, arguing that they have misled patients about the risk of severe gastrointestinal side effects…
